Sunday 15 September 2024

The Pharmaletter

One To Watch

Vaxcyte

A clinical-stage innovation company engineering high-fidelity vaccines.

Company Overview

Want to Update your Company's Profile?


Latest Vaxcyte News

Top-line results further validate potential of Vaxcyte’s VAX-31
3 September 2024
Vaxcyte's pneumococcal vaccine data drives share price jump
18 April 2023
Vaxcyte soars on positive data from Phase I/II study of VAX-24
24 October 2022
More Vaxcyte news >


Today's issue

Biotechnology
The week in pharma: action, reaction and insight – week to September 13, 2024
15 September 2024
Pharmaceutical
ESMO 2024: Positive pooled data from Nuvation Bio highlight taletrectinib benefits
14 September 2024
Biotechnology
ESMO 2024: Merck & Co Phase III KEYNOTE-811 trial Keytruda results
14 September 2024
Pharmaceutical
Aurinia jumps as it restructures board of directors
14 September 2024
Pharmaceutical
Survey shows varied views on impact of new cancer drugs
13 September 2024
Biotechnology
NICE nod for Roche’s Vabysmo
13 September 2024
Biotechnology
ESMO: AstraZeneca and Daiichi Sankyo’s Enhertu achieved a 61.6% PFS
13 September 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze